# Barbiturate Drugs Market

> Barbiturate Drugs Market Research Report By Types (Short-Acting Barbiturates, Long-Acting Barbiturates, Intermediate-Acting Barbiturates), By Applications (Anesthesia, Sedation, Seizure Control, Treatment of Insomnia), By Route of Administration (Oral, Intravenous, Intramuscular), By End Use (Hospitals, Pharmacies, Research Laboratories) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 3.02%
- **2025:** USD 538.2 Million
- **2035:** USD 723.5 Million
- **Key Players:** Par Pharmaceutical (Endo), Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Sanofi, Teva Pharmaceutical Industries, Pfizer, Abbott, Dr. Reddy's Laboratories

**Report ID:** MRFR/HC/41470-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** November 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/barbiturate-drugs-market-43136

---

## Market Summary

## Barbiturate Drugs Market Summary

The global barbiturate drugs market was valued at USD 538.2 Million in 2025 and is projected to reach USD 553.5 Million in 2026, rising to USD 723.5 Million by 2035 at a CAGR of 3.02% over 2026–2035. Two catalysts anchor this outlook. The U.S. FDA's November 2022 approval of Sezaby, the first approved phenobarbital product for neonatal seizures, moved a long-unapproved molecule into a branded, reimbursable framework [5]. Separately, the WHO's 2023 Essential Medicines List kept phenobarbital as a core anticonvulsant therapy, so ministries of health that procure from the list still buy it [2].

Product formats are changing more than the molecules themselves. Hospitals are moving away from reconstituted powders and compounded preparations toward ready-to-use intravenous presentations, bar-coded vials, and infusion protocols tied to smart pumps. Hikma's USD 135 million acquisition of Xellia's U.S. finished-dosage business in September 2024 shows the investment flowing into [sterile injectable](https://www.marketresearchfuture.com/reports/sterile-injectable-market-24682) capacity on which the barbiturate drugs market increasingly depends [20]. Oral phenobarbital still carries outpatient epilepsy volume, but the incremental value now sits in critical care.

North America leads with a 41.6% share, supported by established anaesthesia, neurocritical-care, and neonatal protocols. Asia-Pacific is the fastest-growing region at a 4.18% CAGR, as generic production scales in India and China and epilepsy treatment programmes widen access. Europe ranks second, where legacy brands and hospital tendering keep demand stable. Through 2035, growth will come from clinical settings that have no good substitute for a barbiturate, not from new indications.

## Key Report Takeaways

### • By Drug Type (Value)

- Long-acting agents held a 41.1% share of the barbiturate drugs market in 2025, driven by phenobarbital's role in chronic seizure control
- Ultra-short-acting formulations are expanding at a 4.37% CAGR on demand for rapid-offset anaesthesia induction

### • By Application (Value)

- Epilepsy accounted for a 48.9% share, making it the largest application in the barbiturate drugs market
- Insomnia is the fastest-growing application at a 5.15% CAGR, concentrated in therapy-resistant cases
- Pre-operative Sedation generated USD 121.1 Million in 2025

### • By Route of Administration (Value)

- Oral formulations captured a 61.7% share, reflecting outpatient epilepsy maintenance
- Intravenous delivery is advancing at a 5.88% CAGR as ICU and emergency use rises

### • By Distribution Channel (Value)

- Hospital Pharmacies commanded a 56.3% share, anchored by inpatient stewardship protocols
- Online Pharmacies are growing at a 7.02% CAGR under e-prescribing and PDMP-verified dispensing

### • By Region

- North America leads with a 41.6% share
- Asia-Pacific is the fastest-growing region at a 4.18% CAGR (2026–2035)
- Europe generated USD 142.1 Million in 2025

## Market Size and Forecast (2021–2035)

Market Research Future built the barbiturate drugs market estimate from product-level sales across hospital, retail, and online channels. These figures were cross-checked against controlled-substance quota data, shortage records, and company disclosures, then validated through interviews with hospital pharmacists, anaesthesiologists, and API suppliers. Historical values reflect reported consumption, and forecast values apply scenario-weighted assumptions on substitution, pricing, and regulatory change.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Neonatal and paediatric seizure protocols | +0.5% | North America, Europe | Medium-term (2–4 yr) | [4][5] |
| Epilepsy treatment-gap programmes in low- and middle-income countries | +0.6% | Asia-Pacific, Middle East and Africa, South America | Long-term (≥4 yr) | [1][3] |
| Critical-care and ambulatory anaesthesia demand | +0.4% | Global | Short-term (≤2 yr) | [8][9] |
| Generic API capacity expansion | +0.4% | Asia-Pacific | Medium-term (2–4 yr) |   |
| Neurocritical-care guidelines for refractory intracranial pressure | +0.3% | North America, Europe | Long-term (≥4 yr) | [11] |
| Shortage mitigation through 503B outsourcing facilities | +0.2% | North America | Short-term (≤2 yr) | [9] |

### Neonatal and Paediatric Seizure Protocols

Since the 2011 recommendation, the WHO has recommended phenobarbital as the first-line treatment for newborn seizures [4], and the FDA's 2022 approval of Sezaby provided U.S. hospitals with a preservative-free alternative [5]. Purchasing is moving away from compounded supplies as neonatal [intensive care units](https://www.marketresearchfuture.com/reports/intensive-care-unit-market-21320) formalize order sets around approved products. Higher per-unit value is supported by this change, and pediatric neurology programs are implementing the same procedures.

### Epilepsy Treatment-Gap Programmes

Approximately 80% of the 50 million individuals with epilepsy reside in low- and middle-income nations, where treatment disparities might surpass 75% [1]. A 50% increase in treatment coverage is the goal of the WHO Intersectoral Global Action Plan for 2022–2031 [3]. For national programs attempting to achieve that goal, phenobarbital is the standard option at a few cents per daily dose.

### Critical-Care and Ambulatory Anaesthesia Demand

Methohexital's rapid onset and offset support same-day discharge in ambulatory surgery and electroconvulsive therapy. In intensive care, IV barbiturates are used as rescue agents when first-line sedatives run short. U.S. active drug shortages reached 323 in the first quarter of 2024 [9], which led hospitals to keep qualified barbiturate alternatives on formulary instead of delisting them.

### Generic API Capacity Expansion

India's Production Linked Incentive scheme for key starting materials and APIs commits INR 6,940 crore to domestic production of eligible molecules. Manufacturers are adding controlled-substance API lines alongside those investments, which shortens lead times and reduces reliance on single-country intermediates. Lower conversion costs let Asian suppliers bid in African and Latin American tenders that were previously served from Europe.

### Neurocritical-Care Guidelines

Under the Brain Trauma Foundation's fourth-edition guidelines, high-dose barbiturates remain an option for elevated intracranial pressure that is refractory to maximal standard therapy [11]. Volumes are small, but neurocritical-care centres keep pentobarbital protocols in place and stock it continuously. Each course of therapy is high in value and largely insensitive to price. Trauma network expansion in Asia and the Gulf is extending this demand beyond North America and Europe.

### Shortage Mitigation Through 503B Outsourcing

FDA-registered 503B outsourcing facilities can compound sterile products that appear on the shortage list under current good manufacturing practice. During barbiturate injectable outages, these facilities have supplied ready-to-administer syringes, which keeps usage going while manufacturers recover. The arrangement also creates a secondary buyer of bulk API, adding a demand layer that did not exist before the 2013 Drug Quality and Security Act.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Substitution by benzodiazepines and newer anti-seizure medicines | −0.6% | Global | Long-term (≥4 yr) | [12] |
| Controlled-substance compliance burden | −0.4% | Global | Medium-term (2–4 yr) | [6][15] |
| Safety concerns and geriatric prescribing limits | −0.3% | North America, Europe, Japan | Long-term (≥4 yr) | [13] |
| Supply fragility and manufacturer exits | −0.3% | North America | Short-term (≤2 yr) | [8] |
| Price erosion under tendering and volume-based procurement | −0.2% | Asia-Pacific, Europe | Medium-term (2–4 yr) | [17] |

### Substitution by Newer Agents

Levetiracetam, fosphenytoin, and valproate all prevented benzodiazepine-refractory status epilepticus in around half of the patients in the ESETT trial [12]. Barbiturates are now listed after these alternatives in several guidelines. In routine insomnia therapy, benzodiazepines and non-benzodiazepine hypnotics have also supplanted earlier sedative-hypnotic medications, which restricts outpatient development in high-income markets.

### Controlled-Substance Compliance Burden

Barbiturates are governed by international estimates and import permits under the 1971 UN Convention on Psychotropic Substances [15]. Additional requirements are added by national regimes, such as the U.S. DEA Schedule II–IV categories [6]. Distribution expenses are increased by transaction reporting, vault storage, and quota filings. Because of this, some smaller wholesalers have stopped carrying these medications, which lowers their availability in rural pharmacies.

### Safety and Geriatric Prescribing Limits

The American Geriatrics Society's 2023 Beers Criteria advise avoiding barbiturates in older adults because of high rates of physical dependence and overdose risk at low doses [13]. Many health systems build this guidance into their electronic prescribing alerts. As populations age in Japan, Europe, and North America, the share of eligible outpatients falls.

### Supply Fragility and Manufacturer Exits

Akorn's 2023 shutdown removed a major U.S. supplier of pentobarbital and other sterile injectables overnight. Because few plants hold both the controlled-substance licences and the sterile capacity required, one failure can cause outages lasting several months [8]. Repeated shortages push clinicians toward alternatives that stay in stock, and some of those switches become permanent.

### Price Erosion Under Tendering

China's national volume-based procurement rounds have cut the prices of winning generics by more than 50% on average [17]. Comparable hospital tendering in Southern Europe and the Gulf keeps margins on oral phenobarbital thin. Suppliers without integrated API production struggle to stay profitable at those prices.

## Opportunities

## Barbiturate Drugs Market Opportunities

### Ready-to-Use Neonatal and Paediatric Formulations

Sezaby has shown that a preservative-free neonatal formulation can command a branded price for a molecule that has existed for decades [5]. Weight-based prefilled syringes and oral liquids without alcohol or propylene glycol could replicate that model for other paediatric indications. These are the products most likely to raise value per unit in the long-acting segment.

### Emerging-Market Epilepsy Programmes

Treatment gaps above 75% in low-income settings [1] are a large source of untapped volume. The WHO action plan target makes that volume visible to donors and ministries of health [3]. Suppliers with WHO prequalification, local registration, and tender-ready pricing in Sub-Saharan Africa and South Asia can secure multi-year contracts.

### Intravenous Critical-Care Presentations

Intensive care units want bar-coded, ready-to-administer vials that fit smart-pump drug libraries. Manufacturers that pair IV pentobarbital or methohexital with validated infusion protocols can win formulary preference in group purchasing contracts. The intravenous segment's above-average growth shows this is already happening.

### Data-Enabled Dispensing and New Business Models

Online pharmacies that integrate prescription drug monitoring program (PDMP) checks, identity verification, and adherence tracking produce anonymised real-world data on long-term phenobarbital use. Licensing that data to manufacturers and payers for outcomes studies is a new revenue stream that sits alongside dispensing margins. Subscription refill models for stable epilepsy patients also cut the rate of missed doses.

### Contract Manufacturing for Controlled Sterile Products

Few contract development and manufacturing organisations (CDMOs) hold both controlled-substance licences and aseptic fill-finish capacity. Facilities that offer both can serve originators, 503B outsourcers, and government stockpiles. Long-term take-or-pay agreements make supply more resilient and keep plants running at higher utilisation.

## Future Outlook

## Barbiturate Drugs Market Future Outlook

### Precision Dosing and Clinical Decision Support

Therapeutic drug monitoring linked to [electronic health records](https://www.marketresearchfuture.com/reports/electronic-health-records-market-66597) will make barbiturate dosing more precise, particularly in neonates and intensive care patients, where clearance varies widely. Dosing software built into pump libraries and order sets lowers the risk of oversedation. That reassures clinicians and supports formulary retention. Vendors that bundle drug supply with decision-support content will have an advantage in hospital contracting.

### Neurological Disease Burden

In 2021, more than 3.4 billion people were living with a neurological condition, according to the Global Burden of Disease study [24]. Epilepsy is one of the most treatable of these conditions [1]. As diagnosis expands in South Asia and Africa, phenobarbital demand will grow with it, because it remains the most affordable first-line option on the WHO list [2].

### Supply-Chain Resilience Policy

U.S. shortage counts at record highs [9] have prompted procurement agencies to reward redundancy. Dual-source contract requirements, domestic fill-finish incentives, and strategic stockpiles all favour suppliers with verified backup capacity. Industry consolidation, including the Mallinckrodt–Endo combination [23], will change who controls U.S. sterile barbiturate supply.

### Sustainability and Responsible Manufacturing

Hospital groups are increasingly adding environmental and pharmaceutical-waste criteria to supplier scorecards. API producers that adopt solvent recovery, effluent controls aligned with WHO guidance, and transparent diversion-prevention reporting will qualify more easily for institutional tenders. Sustainability credentials will become a tiebreaker in tenders where prices are otherwise close.

## Segment Insights

## Barbiturate Drugs Market Segmentation

### By Drug Type (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Ultra-short-acting | 4.37% CAGR (2026–2035) | Anaesthesia induction and ECT |
| Short-acting | USD 112.0 Million | Pre-procedural and psychiatric sedation |
| Intermediate-acting | 15.6% share | Combination analgesic and hypnotic products |
| Long-acting | 41.1% share | Chronic epilepsy and neonatal seizures |

Within the barbiturate drugs market, long-acting agents lead because phenobarbital remains the default maintenance therapy for epilepsy and the first-line neonatal option. Ultra-short-acting products such as methohexital are growing fastest, as rapid offset supports same-day discharge after ambulatory procedures and electroconvulsive therapy. Short-acting and intermediate-acting agents serve narrower niches, including procedural sedation and butalbital-containing combinations, where demand is stable but rarely grows quickly.

### By Application (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Epilepsy | 48.9% share | Low-cost first-line therapy in national programmes |
| Insomnia | 5.15% CAGR (2026–2035) | Therapy-resistant cases under specialist care |
| Pre-operative Sedation | USD 121.1 Million | Titratable sedation in fragile patients |
| Medically-Induced Coma | 11.4% share | Refractory intracranial pressure and status epilepticus |

Epilepsy is the largest application in the barbiturate drugs market, supported by WHO essential-medicine status and very low daily treatment cost. Insomnia is growing fastest from a small base, limited to specialist-managed, treatment-resistant patients. Pre-operative Sedation keeps steady hospital demand. Medically-Induced Coma carries the highest value per course, as neurocritical-care units rely on pentobarbital when other measures fail.

### By Route of Administration (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Oral | 61.7% share | Outpatient epilepsy maintenance |
| Intravenous | 5.88% CAGR (2026–2035) | ICU, emergency, and neonatal use |

Oral products dominate the barbiturate drugs market by value because chronic epilepsy patients take tablets every day for years. Intravenous products are growing faster as hospitals standardise protocols for status epilepticus, neonatal seizures, and refractory intracranial pressure. Ready-to-use vials and smart-pump compatibility increase IV value per unit. Oral demand is shifting toward lower-cost emerging-market supply.

### By Distribution Channel (Value)

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 56.3% share | Inpatient injectables under stewardship |
| Retail Pharmacies | USD 202.4 Million | Chronic epilepsy prescriptions |
| Online Pharmacies | 7.02% CAGR (2026–2035) | E-prescribing and PDMP-verified refills |

Hospital pharmacies lead the barbiturate drugs market because high-risk injectables stay under institutional control. Retail pharmacies carry most outpatient phenobarbital, although prior authorisation requirements add friction for patients. Online pharmacies are growing fastest, as verified e-prescribing and home delivery fit patients on stable epilepsy regimens. Their growth still depends on whether controlled-substance telehealth rules remain favourable [7].

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.6% share | Neonatal approvals, ICU injectables, 503B supply |
| Europe | USD 142.1 Million | Legacy brands, hospital tendering, sterile capacity |
| Asia-Pacific | 4.18% CAGR (2026–2035) | Generic API scale-up, epilepsy access programmes |
| South America | 5.3% share | Public-sector procurement, local manufacturing |
| Middle East and Africa | USD 26.4 Million | Donor-funded epilepsy programmes, trauma care build-out |
| Total | USD 538.2 Million | — |

Demand in the barbiturate drugs market follows each region's clinical infrastructure. High-income regions buy value-dense critical-care and neonatal products, while emerging regions account for most oral phenobarbital volume.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 86.5% of regional market | Neonatal phenobarbital adoption, anaesthesia and ICU use |
| Canada | USD 19.0 Million | Provincial formulary coverage for epilepsy |
| Mexico | 3.9% CAGR (2026–2035) | IMSS public procurement of anticonvulsants |

U.S. demand is driven by hospital protocols rather than outpatient prescribing. Neonatal intensive care, electroconvulsive therapy anaesthesia, and refractory intracranial pressure management keep value high even as the number of outpatient scripts falls. The 2024 extension of DEA [telemedicine](https://www.marketresearchfuture.com/reports/telemedicine-market-2216) flexibilities allowed controlled-medicine refills to continue through digital channels [7]. Canada relies on provincial drug plans, and Mexico's growth depends on how much centralised IMSS purchasing it secures.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 22.4% of regional market | Hospital anaesthesia and neurology volumes |
| United Kingdom | USD 25.6 Million | NHS neonatal and epilepsy pathways |
| France | 2.1% CAGR (2026–2035) | Gardenal brand loyalty in chronic epilepsy |
| Italy | 13.2% of regional market | Regional hospital tenders |
| Spain | USD 13.4 Million | Public hospital procurement |
| Rest of Europe | 1.9% CAGR (2026–2035) | Eastern European generic substitution |

Europe has the most mature demand of any region. Established phenobarbital brands such as Sanofi's Gardenal hold outpatient share in France, while Germany and the United Kingdom concentrate on hospital use. Tender-driven pricing in Italy and Spain limits margins, but it also guarantees volume for suppliers that win national or regional lots. EU controlled-substance rules require import and export authorisations for every cross-border shipment [15], which favours suppliers manufacturing inside the bloc.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 36.5% of regional market | Volume-based procurement and hospital expansion |
| India | 5.6% CAGR (2026–2035) | PLI-backed API production and public epilepsy programmes |
| Japan | USD 22.1 Million | Neurocritical care and anaesthesia |
| South Korea | 3.9% CAGR (2026–2035) | Tertiary hospital ICU capacity |
| Australia | 6.4% of regional market | PBS-listed anticonvulsants |
| Rest of Asia-Pacific | USD 9.2 Million | Donor-supported epilepsy access in Southeast Asia |

Asia-Pacific is where the barbiturate drugs market adds the most volume. In China, procurement reform has cut prices but widened hospital access, so unit volumes have risen. India's incentive scheme is building API depth that supplies both domestic programmes and export tenders. Japan's ageing population restricts outpatient use, but its intensive care units remain dependable buyers of premium injectables.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.0% of regional market | SUS public supply of anticonvulsants |
| Argentina | 3.4% CAGR (2026–2035) | Local generic manufacturing |
| Rest of South America | USD 5.4 Million | Pan-American Health Organization (PAHO) Strategic Fund purchasing |

Brazil's unified health system (SUS) distributes phenobarbital free of charge through primary care, which accounts for most of the region's volume. Argentina's local producers compete on cost and keep import dependence low. Smaller markets buy through pooled procurement mechanisms, so suppliers need tender-ready pricing and WHO-aligned quality documentation.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 38.5% of regional market | Trauma and neurocritical-care investment |
| South Africa | USD 6.3 Million | Essential medicines list procurement |
| Rest of Middle East and Africa | 3.7% CAGR (2026–2035) | Epilepsy treatment-gap programmes |

Gulf states are buying premium IV products for newly built trauma and neurology centres. In Sub-Saharan Africa, demand is volume-driven, and phenobarbital supports national epilepsy programmes in line with WHO guidance [1]. Cold-chain logistics are not needed for oral products, but import permit delays under international control rules often slow deliveries.

## Competitive Benchmarking

## Competitive Benchmarking

The barbiturate drugs market is moderately fragmented. The estimated Herfindahl-Hirschman Index is around 850–1,000, and the five largest suppliers hold roughly 38–45% of revenue. Sterile injectables are concentrated among a few licensed U.S. and European manufacturers, while oral generics are spread across many Indian, Chinese, and regional producers. Recent bankruptcies, acquisitions, and plant closures have changed supplier positions more than product innovation has.

| Company | Est. Revenue Share Range | Key Offerings for Barbiturates | Strategic Positioning |
| --- | --- | --- | --- |
| Par Pharmaceutical (Endo) | ~8–11% | Methohexital sodium for injection (Brevital); sterile injectables | U.S. anaesthesia incumbent, now part of the Mallinckrodt–Endo group |
| Hikma Pharmaceuticals | ~7–10% | Phenobarbital sodium injection; critical-care injectables | Scaling U.S. sterile capacity after the Xellia acquisition |
| Sun Pharmaceutical Industries | ~6–9% | Sezaby (phenobarbital sodium powder); oral generics | Branded neonatal niche plus emerging-market volume |
| Sanofi | ~5–8% | Gardenal (phenobarbital) | Legacy brand equity in France and Francophone Africa |
| Teva Pharmaceutical Industries | ~5–7% | Barbiturate-containing oral generics, including butalbital combinations | Portfolio rationalisation under its growth strategy |
| Pfizer | ~4–7% | Hospira-legacy critical-care and anaesthesia injectables | Hospital-channel scale and group purchasing contracts |
| Abbott | ~3–6% | Originator heritage in pentobarbital and thiopental; emerging-market branded generics | Selective presence through branded generics |
| Dr. Reddy's Laboratories | ~3–5% | Generic CNS formulations and APIs | Low-cost supplier for tender markets |
| Ethypharm | ~2–4% | Hospital and CNS injectables in Europe | Specialty hospital focus |
| Samarth Life Science Pvt. Ltd | ~1–3% | Thiopentone sodium and anaesthesia injectables | Indian domestic and export tenders |
| Akorn Operating Company LLC | <1% | Former Nembutal (pentobarbital sodium) supplier | Operations ceased in 2023; product rights redistributed |

## Recent News & Developments

## Recent News & Developments

- Akorn Operating Company LLC (February 2023): Akorn shut down its U.S. operations and filed for Chapter 7 liquidation, removing a major pentobarbital supplier and triggering hospital shortages
- Teva Pharmaceutical Industries (May 2023): Teva launched its "Pivot to Growth" strategy, which prioritises generic portfolio optimisation and affects its older CNS products
- World Health Organization (July 2023): The 23rd Model List of Essential Medicines kept phenobarbital as a core anticonvulsant, preserving its place in public procurement [2]
- ASHP (April 2024): U.S. active drug shortages hit a record 323 in Q1 2024, raising the value of qualified barbiturate injectable supply [9]
- Endo, Inc. (April 2024): Endo emerged from Chapter 11 with the Par sterile injectables business, including methohexital, intact [18]
- Hikma Pharmaceuticals (September 2024): Hikma completed its USD 135 million acquisition of Xellia's U.S. finished-dosage business, adding injectable capacity in Cleveland, Ohio [20]
- DEA and HHS (November 2024): The agencies extended telemedicine flexibilities for controlled-substance prescribing through 31 December 2025, supporting online refill channels [7]
- Mallinckrodt and Endo (March 2025): The two companies agreed to a USD 6.7 billion combination and plan to merge their generics and sterile injectables operations for a later separation [23]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Covers ultra-short-, short-, intermediate-, and long-acting barbiturate drugs in oral and intravenous forms, sold through hospital, retail, and online pharmacies for epilepsy, insomnia, sedation, and induced coma |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 538.2 Million |
| Market Size in 2035 | USD 723.5 Million |
| CAGR (2026–2035) | 3.02% |
| Fastest Growing Segments | Online Pharmacies (7.02% CAGR); Intravenous (5.88% CAGR); Insomnia (5.15% CAGR); Ultra-short-acting (4.37% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Par Pharmaceutical, Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Sanofi, Teva Pharmaceutical Industries, Pfizer, Abbott, Dr. Reddy's Laboratories, Ethypharm, Samarth Life Science Pvt. Ltd., Akorn Operating Company LLC |
| Valuation Currency | USD Million |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What should hospital buyers prioritise when sourcing intravenous products in the barbiturate drugs market?**
A: Supplier redundancy matters more than unit price, because single-source sterile injectables appear most often in shortage databases [8]. Contracts that require two qualified manufacturers and ready-to-use presentations reduce the risk of forced substitution during outages.

**Q: How does controlled-substance scheduling differ across barbiturate products?**
A: Scheduling depends on each product's abuse potential, not on the drug class. In the United States, pentobarbital is Schedule II, while phenobarbital and methohexital are Schedule IV [6]. Each tier has different quota, storage, and record-keeping obligations.

**Q: Can online pharmacies dispense phenobarbital after a telehealth consultation?**
A: Temporary DEA–HHS flexibilities allowed controlled medicines to be prescribed by telemedicine without a prior in-person visit, and they were extended through 31 December 2025 [7]. Operators should track the final special-registration rule before expanding further.

**Q: Why is thiopental largely unavailable in the U.S. barbiturate drugs market?**
A: Hospira, the sole U.S. manufacturer, stopped producing sodium thiopental in 2011, and European export restrictions followed. Propofol and methohexital have since taken over its role in anaesthesia induction.

**Q: Is API manufacturing an attractive investment within the barbiturate drugs market?**
A: Selectively. India's INR 6,940 crore PLI scheme improves returns on eligible API lines [16], but quota approvals and modest volumes mean investors should secure supply contracts before building controlled-substance capacity.

**Q: How do barbiturates compare with propofol for procedural sedation?**
A: Methohexital recovers quickly and has weaker anticonvulsant effects, which makes it the preferred agent for electroconvulsive therapy. Propofol remains the default for most other day-case procedures because of its antiemetic profile.

**Q: What new use cases could expand the barbiturate drugs market?**
A: Phenobarbital protocols for severe alcohol withdrawal are the most credible expansion area for the barbiturate drugs market, and they appear as an option in ASAM guidance [25]. Wider adoption would add steady inpatient volume without any new molecule development.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/barbiturate-drugs-market-43136*
